Anticoagulation in High Bleeding Risk Cancer Patients - Dr Nolukholo Ncete

Learn about managing anticoagulation in cancer patients with high bleeding risk in this comprehensive lecture. Explore therapeutic options for cancer-associated thrombosis (CAT), examining evidence for various drugs. Delve into conditions that increase bleeding risk in CAT patients on anticoagulation. Discover monitoring techniques for anticoagulants and review a treatment algorithm based on platelet count. Cover topics including incidental VTEs, cancer-associated risk factors, LMWH versus VKA and DOACs, considerations for prescribing DOACs, thrombocytopenia, renal and hepatic impairment, use of antiplatelet agents, and special patient populations. Gain insights on IVC filters, mechanical prophylaxis, DOAC testing, LMWH monitoring, and warfarin initiation.

Intro
Introduction continued...
Incidental VTE's
Cancer-associated risk factors for VTE
What the management may look like?
LMWH versus VKA
LMWH versus DOACs
Edoxaban
Apixaban
Considerations prior to prescribing DOACs in CAT
Thrombocytopenia continued...
Renal impairment & LMWH
Dosing recommendations according to creatinine clearance in mL/min
GIT/GU malignancy
Hepatic impairment continued...
Use of antiplatelet agents
Low body weight
Abnormal uterine bleeding
Intracranial lesions
The role of IVC filters
Mechanical prophylaxis
When to measure DOACs?
DOAC testing continued...
Monitoring of patients on LMWH
Warfarin initiation